Visirna Therapeutics HK
CompanyHong Kong
Visirna Therapeutics HK develops 2 assets, the furthest approved (plozasiran in familial chylomicronemia syndrome). Mostly oligonucleotide acting on APOC3; based in Hong Kong.
- 2
- Assets
- Furthest stage
- Approved
- 2
- Trials
- 6
- Signals
Pipeline
2Silences hepatic APOC3 expression to lower apolipoprotein C-III and circulating triglycerides.
Approved, Oligonucleotide, APOC3, familial chylomicronemia syndrome, severe hypertriglyceridemia (Phase 3)
siRNA targeting HSD17B13 mRNA to downregulate hepatic HSD17B13 expression
Phase 2, Oligonucleotide, NASH
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Signals11
- Similar companies6